Joyce Cheung-Flynn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joyce Cheung-Flynn has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Colleen Brophy
Department of Vascular Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
9 shared publications- Kyle M. Hocking
Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
6 shared publications Padmini Komalavilas
Department of Surgery, Vanderbilt University, Nashville, TN, USA
5 shared publications- Colleen M. Brophy
Division of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, D-5237 Medical Center North, 1161 22nd Avenue South, Nashville, TN 37232, United States; Veterans Affairs Medical Center, VA Tennessee Valley Healthcare System, 1310 24th Avenue, South, Nashville, TN 37212, United States
3 shared publications Fan Dong Li
Department of Surgery, General Hospital of Jinan Military District, Jinan, China
3 shared publicationsMadeleine Morelli
Department of Vascular Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
3 shared publications
Latest Publications
- Open Access
- 16 February 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (2) , 142-153
Mitigating sepsis-induced vascular endothelial dysfunction through Niban phosphorylation
Introduction: Endothelial dysfunction is a hallmark of sepsis pathophysiology, driven by inflammation, oxidative stress, and endoplasmic reticulum (ER) stress, leading to vascular abnormalities and organ failure. Niban, a multifunctional cellular stress response protein, regulates endothelial homeostasis, with its phosphorylation playing a critical role in mitigating ER stress. We hypothesized that sepsis-induced endothelial dysfunction in the aorta is driven by reduced Niban phosphorylation, which increases ER stress, but can be restored by NiPp, a cell-permeant phosphopeptide mimetic designed to replicate phosphorylated Niban. Methods: Rats were subjected to a cecal slurry model of polymicrobial sepsis. Molecular markers of ER stress and Niban phosphorylation were analyzed using Western blot, and the vascular reactivity of septic aortae was assessed in muscle baths. Ex vivo NiPp treatment on septic aortic dysfunction was also evaluated. The effects of ER stressors or circulating sepsis mediators, including lipopolysaccharides, interleukin-1β, and cell-free hemoglobin, on endothelial function in healthy aortic rings were tested with or without NiPp. Results: Septic aortas exhibited reduced Niban and endothelial nitric oxide synthase phosphorylation, as well as increased glucose-regulated protein 78 levels. Ex vivo treatment with NiPp improved endothelial dysfunction in septic rat aortas. Moreover, NiPp improved endothelium-dependent relaxation in aortic rings exposed to the ER stressor or any of the circulating sepsis mediators ex vivo. Conclusion: Together, these findings highlight reduced Niban phosphorylation as an important driver of vascular endothelial dysfunction during sepsis, and suggest a mechanistic link between sepsis, reduced Niban phosphorylation, and heightened ER stress.
- 16 February 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (2) , 142-153
Open AccessMitigating sepsis-induced vascular endothelial dysfunction through Niban phosphorylation
Introduction: Endothelial dysfunction is a hallmark of sepsis pathophysiology, driven by inflammation, oxidative stress, and endoplasmic reticulum (ER) stress, leading to vascular abnormalities and organ failure. Niban, a multifunctional cellular stress response protein, regulates endothelial homeostasis, with its phosphorylation playing a critical role in mitigating ER stress. We hypothesized that sepsis-induced endothelial dysfunction in the aorta is driven by reduced Niban phosphorylation, which increases ER stress, but can be restored by NiPp, a cell-permeant phosphopeptide mimetic designed to replicate phosphorylated Niban. Methods: Rats were subjected to a cecal slurry model of polymicrobial sepsis. Molecular markers of ER stress and Niban phosphorylation were analyzed using Western blot, and the vascular reactivity of septic aortae was assessed in muscle baths. Ex vivo NiPp treatment on septic aortic dysfunction was also evaluated. The effects of ER stressors or circulating sepsis mediators, including lipopolysaccharides, interleukin-1β, and cell-free hemoglobin, on endothelial function in healthy aortic rings were tested with or without NiPp. Results: Septic aortas exhibited reduced Niban and endothelial nitric oxide synthase phosphorylation, as well as increased glucose-regulated protein 78 levels. Ex vivo treatment with NiPp improved endothelial dysfunction in septic rat aortas. Moreover, NiPp improved endothelium-dependent relaxation in aortic rings exposed to the ER stressor or any of the circulating sepsis mediators ex vivo. Conclusion: Together, these findings highlight reduced Niban phosphorylation as an important driver of vascular endothelial dysfunction during sepsis, and suggest a mechanistic link between sepsis, reduced Niban phosphorylation, and heightened ER stress.
- Open Access
- 29 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 335
Endothelial dysfunction in aging associated with reduced Niban phosphorylation
Background: Cardiovascular diseases are the leading cause of mortality worldwide, with aging and endothelial dysfunction being key contributors to its progression. Age-related vascular dysfunction is characterized by impaired endothelial-dependent relaxation, increased vascular inflammation, and heightened susceptibility to injury, all of which exacerbate cardiovascular risk. The multi-functional protein Niban restores vascular function following injury, with reduced Niban phosphorylation linked to activation of mitogen-activated protein kinase (MAPK) pathways. We hypothesized that reduced Niban phosphorylation and increased inflammatory MAPK signaling would be associated with vascular dysfunction in aging that can be attenuated by NiPp, a cell permeant phosphomimetic peptide of Niban. Methods and results: Aortas from young (3-months-old, N = 8) and aged (20- to 23-month-old N = 8) rats were assessed for vascular reactivity as well as protein levels and protein phosphorylation. Aged aortas displayed impaired contractility, endothelial-dependent relaxation, reduced phosphorylated Niban levels, and increased phosphorylation of inflammatory MAPK pathway elements including c-Jun N-terminal kinase, MAP kinase-activated protein kinase 2, phosphorylated cAMP response element-binding protein, and downstream vascular cell adhesion molecule-1. Aged aortas also exhibited greater IL-1β-induced loss of endothelial-dependent relaxation ex vivo, which was attenuated by NiPp treatment. Conclusion: These results identify reduced Niban phosphorylation and increased MAPK signaling as contributors to age-related endothelial dysfunction and highlight Niban phosphorylation as a possible target for treating vascular aging and associated cardiovascular diseases.
- 29 January 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 335
Open AccessEndothelial dysfunction in aging associated with reduced Niban phosphorylation
Background: Cardiovascular diseases are the leading cause of mortality worldwide, with aging and endothelial dysfunction being key contributors to its progression. Age-related vascular dysfunction is characterized by impaired endothelial-dependent relaxation, increased vascular inflammation, and heightened susceptibility to injury, all of which exacerbate cardiovascular risk. The multi-functional protein Niban restores vascular function following injury, with reduced Niban phosphorylation linked to activation of mitogen-activated protein kinase (MAPK) pathways. We hypothesized that reduced Niban phosphorylation and increased inflammatory MAPK signaling would be associated with vascular dysfunction in aging that can be attenuated by NiPp, a cell permeant phosphomimetic peptide of Niban. Methods and results: Aortas from young (3-months-old, N = 8) and aged (20- to 23-month-old N = 8) rats were assessed for vascular reactivity as well as protein levels and protein phosphorylation. Aged aortas displayed impaired contractility, endothelial-dependent relaxation, reduced phosphorylated Niban levels, and increased phosphorylation of inflammatory MAPK pathway elements including c-Jun N-terminal kinase, MAP kinase-activated protein kinase 2, phosphorylated cAMP response element-binding protein, and downstream vascular cell adhesion molecule-1. Aged aortas also exhibited greater IL-1β-induced loss of endothelial-dependent relaxation ex vivo, which was attenuated by NiPp treatment. Conclusion: These results identify reduced Niban phosphorylation and increased MAPK signaling as contributors to age-related endothelial dysfunction and highlight Niban phosphorylation as a possible target for treating vascular aging and associated cardiovascular diseases.
- Open Access
Reactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH
Background: Products of lipid peroxidation include a number of reactive lipid aldehydes including reactive dicarbonyl electrophiles (DEs) and contribute to disease processes. DEs play a significant role in the development and progression of metabolic-associated steatotic liver disease (MASLD) by contributing to oxidative stress, inflammation, protein dysfunction, and mitochondrial impairment. Reducing DE stress may be a potential strategy for managing MASLD. We hypothesized that the DE scavenger 2-hydroxybenzylamine (2-HOBA) would reduce liver injury by reducing liver protein adduct formation by DE in mouse models of MASLD. Methods: Protein adducts were measured in human livers by immunohistochemistry and immunoblot. The effects of 2-HOBA were assessed in two different mouse models of MASLD. Results: Isolevuglandin (IsoLG) protein adducts were increased in MASH-staged human livers relative to histologically normal controls. Diet-Induced Animal Model of Nonalcoholic Fatty Liver Disease (DIAMOND) mice treated with 2-HOBA exhibited significantly lower fibrosis scores (* p = 0.012) and reduced liver transaminases (AST, p = 0.03) and ALT, p = 0.012) by over 40%. In STAM (Stelic Animal Model) mice, 2-HOBA improved NAFLD activity scores (p = 0.03, NAS), hyperglycemia, and inflammatory cytokines and reduced serum F2-isoprostanes (IsoPs) by 30%, p = 0.05. These improvements were absent mRNA changes in hepatic antioxidant enzymes (Cat, Gpx1, or Sod2) or ROS-generating proteins (p22PHOX, p47PHOX, NOX4 or COX1). Conclusions: DE scavenging with 2-HOBA may be a promising therapeutic strategy for managing MASLD. While findings are currently limited to male mice, a nutraceutical that reduces liver fibrosis could significantly improve the management of MASH by offering a non-invasive treatment option to potentially slow or reverse liver scarring, delay progression to cirrhosis, and improve patient outcomes, while also providing a potential treatment option for patients who may not be suitable for other interventions like liver transplantation.
Open AccessReactive Dicarbonyl Scavenging with 2-Hydroxybenzylamine Improves MASH
Background: Products of lipid peroxidation include a number of reactive lipid aldehydes including reactive dicarbonyl electrophiles (DEs) and contribute to disease processes. DEs play a significant role in the development and progression of metabolic-associated steatotic liver disease (MASLD) by contributing to oxidative stress, inflammation, protein dysfunction, and mitochondrial impairment. Reducing DE stress may be a potential strategy for managing MASLD. We hypothesized that the DE scavenger 2-hydroxybenzylamine (2-HOBA) would reduce liver injury by reducing liver protein adduct formation by DE in mouse models of MASLD. Methods: Protein adducts were measured in human livers by immunohistochemistry and immunoblot. The effects of 2-HOBA were assessed in two different mouse models of MASLD. Results: Isolevuglandin (IsoLG) protein adducts were increased in MASH-staged human livers relative to histologically normal controls. Diet-Induced Animal Model of Nonalcoholic Fatty Liver Disease (DIAMOND) mice treated with 2-HOBA exhibited significantly lower fibrosis scores (* p = 0.012) and reduced liver transaminases (AST, p = 0.03) and ALT, p = 0.012) by over 40%. In STAM (Stelic Animal Model) mice, 2-HOBA improved NAFLD activity scores (p = 0.03, NAS), hyperglycemia, and inflammatory cytokines and reduced serum F2-isoprostanes (IsoPs) by 30%, p = 0.05. These improvements were absent mRNA changes in hepatic antioxidant enzymes (Cat, Gpx1, or Sod2) or ROS-generating proteins (p22PHOX, p47PHOX, NOX4 or COX1). Conclusions: DE scavenging with 2-HOBA may be a promising therapeutic strategy for managing MASLD. While findings are currently limited to male mice, a nutraceutical that reduces liver fibrosis could significantly improve the management of MASH by offering a non-invasive treatment option to potentially slow or reverse liver scarring, delay progression to cirrhosis, and improve patient outcomes, while also providing a potential treatment option for patients who may not be suitable for other interventions like liver transplantation.
- 12 January 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (1) , 1-11
The Cell Permeant Phosphopetpide mimetic of VASP Alleviates Motor Function Deficits After Experimental Subarachnoid Hemorrhage
Subarachnoid hemorrhage (SAH) due to the rupture of an intracranial aneurysm leads to delayed vasospasm and neuroischemia, which can result in profound neurologic deficit and death. Therapeutic options after SAH are currently limited to hemodynamic optimization and nimodipine, which have limited clinical efficacy. Experimental SAH results in cerebral vasospasm have demonstrated the downregulation of nitric oxide (NO)-protein kinase G (PKG) signaling elements. VP3 is a novel cell permeant phosphopeptide mimetic of VASP, a substrate of PKG and an actin-associated protein that modulates vasorelaxation in vascular smooth muscle cells. In this study, we determined that intravenous administration of high doses of VP3 did not induce systemic hypotension in rats except at the maximal soluble dose, implying that VP3 is well-tolerated and has a wide therapeutic window. Using a single cisterna magna injection rat model of SAH, we demonstrated that intravenous administration of low-dose VP3 after SAH improved neurologic deficits for up to 14 days as determined by the rotarod test. These findings suggest that strategies aimed at targeting the cerebral vasculature with VP3 may improve neurologic deficits associated with SAH.
- 12 January 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (1) , 1-11
The Cell Permeant Phosphopetpide mimetic of VASP Alleviates Motor Function Deficits After Experimental Subarachnoid Hemorrhage
Subarachnoid hemorrhage (SAH) due to the rupture of an intracranial aneurysm leads to delayed vasospasm and neuroischemia, which can result in profound neurologic deficit and death. Therapeutic options after SAH are currently limited to hemodynamic optimization and nimodipine, which have limited clinical efficacy. Experimental SAH results in cerebral vasospasm have demonstrated the downregulation of nitric oxide (NO)-protein kinase G (PKG) signaling elements. VP3 is a novel cell permeant phosphopeptide mimetic of VASP, a substrate of PKG and an actin-associated protein that modulates vasorelaxation in vascular smooth muscle cells. In this study, we determined that intravenous administration of high doses of VP3 did not induce systemic hypotension in rats except at the maximal soluble dose, implying that VP3 is well-tolerated and has a wide therapeutic window. Using a single cisterna magna injection rat model of SAH, we demonstrated that intravenous administration of low-dose VP3 after SAH improved neurologic deficits for up to 14 days as determined by the rotarod test. These findings suggest that strategies aimed at targeting the cerebral vasculature with VP3 may improve neurologic deficits associated with SAH.
- Open Access
- 8 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (19)
Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch
Vascular procedures, such as stenting, angioplasty, and bypass grafting, often fail due to intimal hyperplasia (IH), wherein contractile vascular smooth muscle cells (VSMCs) dedifferentiate to synthetic VSMCs, which are highly proliferative, migratory, and fibrotic. Previous studies suggest MAPK-activated protein kinase 2 (MK2) inhibition may limit VSMC proliferation and IH, although the molecular mechanism underlying the observation remains unclear. We demonstrated here that MK2 inhibition blocked the molecular program of contractile to synthetic dedifferentiation and mitigated IH development. Molecular markers of the VSMC contractile phenotype were sustained over time in culture in rat primary VSMCs treated with potent, long-lasting MK2 inhibitory peptide nanopolyplexes (MK2i-NPs), a result supported in human saphenous vein specimens cultured ex vivo. RNA-Seq of MK2i-NP–treated primary human VSMCs revealed programmatic switching toward a contractile VSMC gene expression profile, increasing expression of antiinflammatory and contractile-associated genes while lowering expression of proinflammatory, promigratory, and synthetic phenotype–associated genes. Finally, these results were confirmed using an in vivo rabbit vein graft model where brief, intraoperative treatment with MK2i-NPs decreased IH and synthetic phenotype markers while preserving contractile proteins. These results support further development of MK2i-NPs as a therapy for blocking VSMC phenotype switch and IH associated with cardiovascular procedures.
- 8 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (19)
Open AccessTherapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch
Vascular procedures, such as stenting, angioplasty, and bypass grafting, often fail due to intimal hyperplasia (IH), wherein contractile vascular smooth muscle cells (VSMCs) dedifferentiate to synthetic VSMCs, which are highly proliferative, migratory, and fibrotic. Previous studies suggest MAPK-activated protein kinase 2 (MK2) inhibition may limit VSMC proliferation and IH, although the molecular mechanism underlying the observation remains unclear. We demonstrated here that MK2 inhibition blocked the molecular program of contractile to synthetic dedifferentiation and mitigated IH development. Molecular markers of the VSMC contractile phenotype were sustained over time in culture in rat primary VSMCs treated with potent, long-lasting MK2 inhibitory peptide nanopolyplexes (MK2i-NPs), a result supported in human saphenous vein specimens cultured ex vivo. RNA-Seq of MK2i-NP–treated primary human VSMCs revealed programmatic switching toward a contractile VSMC gene expression profile, increasing expression of antiinflammatory and contractile-associated genes while lowering expression of proinflammatory, promigratory, and synthetic phenotype–associated genes. Finally, these results were confirmed using an in vivo rabbit vein graft model where brief, intraoperative treatment with MK2i-NPs decreased IH and synthetic phenotype markers while preserving contractile proteins. These results support further development of MK2i-NPs as a therapy for blocking VSMC phenotype switch and IH associated with cardiovascular procedures.
- Open Access
- 12 May 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (7) , 9180-9191
A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury
Vascular injury leads to membrane disruption, ATP release, and endothelial dysfunction. Increases in the phosphorylation of p38 mitogen‐activated protein kinase (p38 MAPK) and decreases in the phosphorylation of Niban, a protein implicated in ER stress and apoptosis, are associated with vascular injury. A cell permeant phosphopeptide mimetic of Niban (NiPp) was generated. The effects of NiPp in restoring endothelial function were determined ex vivo using intact rat aortic tissue (RA) after pharmacological activation of p38 MAPK and also in multiple clinically relevant injury models. Anisomycin (Aniso) increased p38 MAPK phosphorylation and reduced endothelial‐dependent relaxation in RA. Treatment with NiPp prevented Ansio‐induced reduction in endothelial function and increases in p38 MAPK phosphorylation. NiPp treatment also restored endothelial function after stretch injury (subfailure stretch), treatment with acidic Normal Saline (NS), and P2X7R activation with 2′(3′)‐O‐(4‐Benzoylbenzoyl)adenosine 5′‐triphosphate (BzATP). Aged, diseased, human saphenous vein (HSV) remnants obtained from patients undergoing coronary bypass surgical procedures have impaired endothelial function. Treatment of these HSV segments with NiPp improved endothelial‐dependent relaxation. Kinome screening experiments indicated that NiPp inhibits p38 MAPK. These data demonstrate that p38 MAPK and Niban signaling have a role in endothelial function, particularly in response to injury. Niban may represent an endogenous regulator of p38 MAPK activation. The NiPp peptide may serve as an experimental tool to further elucidate p38 MAPK regulation and as a potential therapeutic for endothelial dysfunction.
- 12 May 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (7) , 9180-9191
Open AccessA cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury
Vascular injury leads to membrane disruption, ATP release, and endothelial dysfunction. Increases in the phosphorylation of p38 mitogen‐activated protein kinase (p38 MAPK) and decreases in the phosphorylation of Niban, a protein implicated in ER stress and apoptosis, are associated with vascular injury. A cell permeant phosphopeptide mimetic of Niban (NiPp) was generated. The effects of NiPp in restoring endothelial function were determined ex vivo using intact rat aortic tissue (RA) after pharmacological activation of p38 MAPK and also in multiple clinically relevant injury models. Anisomycin (Aniso) increased p38 MAPK phosphorylation and reduced endothelial‐dependent relaxation in RA. Treatment with NiPp prevented Ansio‐induced reduction in endothelial function and increases in p38 MAPK phosphorylation. NiPp treatment also restored endothelial function after stretch injury (subfailure stretch), treatment with acidic Normal Saline (NS), and P2X7R activation with 2′(3′)‐O‐(4‐Benzoylbenzoyl)adenosine 5′‐triphosphate (BzATP). Aged, diseased, human saphenous vein (HSV) remnants obtained from patients undergoing coronary bypass surgical procedures have impaired endothelial function. Treatment of these HSV segments with NiPp improved endothelial‐dependent relaxation. Kinome screening experiments indicated that NiPp inhibits p38 MAPK. These data demonstrate that p38 MAPK and Niban signaling have a role in endothelial function, particularly in response to injury. Niban may represent an endogenous regulator of p38 MAPK activation. The NiPp peptide may serve as an experimental tool to further elucidate p38 MAPK regulation and as a potential therapeutic for endothelial dysfunction.
- 1 July 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 282, 110-119
Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes
- 1 July 2018
- Published by Elsevier in Journal of Controlled Release
- Vol. 282, 110-119
Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes
- 13 September 2017
- Published by Springer Nature in Purinergic Signalling
- Vol. 13 (4) , 579-590
P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis
Human saphenous vein (HSV) is harvested and prepared prior to implantation as an arterial bypass graft. Injury and the response to injury from surgical harvest and preparation trigger cascades of molecular events and contribute to graft remodeling and intimal hyperplasia. Apoptosis is an early response after implantation that contributes the development of neointimal lesions. Here, we showed that surgical harvest and preparation of HSV leads to vasomotor dysfunction, increased apoptosis and downregulation of the phosphorylation of the anti-apoptotic protein, Niban. A model of subfailure overstretch injury in rat aorta (RA) was used to demonstrate impaired vasomotor function, increased extracellular ATP (eATP) release, and increased apoptosis following pathological vascular injury. The subfailure overstretch injury was associated with activation of p38 MAPK stress pathway and decreases in the phosphorylation of the anti-apoptotic protein Niban. Treatment of RA after overstretch injury with antagonists to purinergic P2X7 receptor (P2X7R) antagonists or P2X7R/pannexin (PanX1) complex, but not PanX1 alone, restored vasomotor function. Inhibitors to P2X7R and PanX1 reduced stretch-induced eATP release. P2X7R/PanX1 antagonism led to decrease in p38 MAPK phosphorylation, restoration of Niban phosphorylation and increases in the phosphorylation of the anti-apoptotic protein Akt in RA and reduced TNFα-stimulated caspase 3/7 activity in cultured rat vascular smooth muscle cells. In conclusion, inhibition of P2X7R after overstretch injury restored vasomotor function and inhibited apoptosis. Treatment with P2X7R/PanX1 complex inhibitors after harvest and preparation injury of blood vessels used for bypass conduits may prevent the subsequent response to injury that lead to apoptosis and represents a novel therapeutic approach to prevent graft failure.
- 13 September 2017
- Published by Springer Nature in Purinergic Signalling
- Vol. 13 (4) , 579-590
P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis
Human saphenous vein (HSV) is harvested and prepared prior to implantation as an arterial bypass graft. Injury and the response to injury from surgical harvest and preparation trigger cascades of molecular events and contribute to graft remodeling and intimal hyperplasia. Apoptosis is an early response after implantation that contributes the development of neointimal lesions. Here, we showed that surgical harvest and preparation of HSV leads to vasomotor dysfunction, increased apoptosis and downregulation of the phosphorylation of the anti-apoptotic protein, Niban. A model of subfailure overstretch injury in rat aorta (RA) was used to demonstrate impaired vasomotor function, increased extracellular ATP (eATP) release, and increased apoptosis following pathological vascular injury. The subfailure overstretch injury was associated with activation of p38 MAPK stress pathway and decreases in the phosphorylation of the anti-apoptotic protein Niban. Treatment of RA after overstretch injury with antagonists to purinergic P2X7 receptor (P2X7R) antagonists or P2X7R/pannexin (PanX1) complex, but not PanX1 alone, restored vasomotor function. Inhibitors to P2X7R and PanX1 reduced stretch-induced eATP release. P2X7R/PanX1 antagonism led to decrease in p38 MAPK phosphorylation, restoration of Niban phosphorylation and increases in the phosphorylation of the anti-apoptotic protein Akt in RA and reduced TNFα-stimulated caspase 3/7 activity in cultured rat vascular smooth muscle cells. In conclusion, inhibition of P2X7R after overstretch injury restored vasomotor function and inhibited apoptosis. Treatment with P2X7R/PanX1 complex inhibitors after harvest and preparation injury of blood vessels used for bypass conduits may prevent the subsequent response to injury that lead to apoptosis and represents a novel therapeutic approach to prevent graft failure.
- Open Access
- 29 September 2016
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 4, 75
Subfailure Overstretch Injury Leads to Reversible Functional Impairment and Purinergic P2X7 Receptor Activation in Intact Vascular Tissue
Vascular stretch injury is associated with blunt trauma, vascular surgical procedures, and harvest of human saphenous vein for use in vascular bypass grafting. A model of subfailure overstretch in rat abdominal aorta was developed to characterize surgical vascular stretch injury. Longitudinal stretch of rat aorta was characterized ex vivo. Stretch to the haptic endpoint where the tissues would no longer lengthen, occurred at twice the resting length. The stress produced at this length was greater than physiologic mechanical forces but well below the level of mechanical disruption. Functional responses were determined in a muscle bath and this subfailure overstretch injury led to impaired smooth muscle function that was partially reversed by treatment with purinergic receptor (P2X7R) antagonists. These data suggest that vasomotor dysfunction caused by subfailure overstretch injury may be due to activation of P2X7R. These studies have implications for our understanding of mechanical stretch injury of blood vessels and offer novel therapeutic opportunities.
- 29 September 2016
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 4, 75
Open AccessSubfailure Overstretch Injury Leads to Reversible Functional Impairment and Purinergic P2X7 Receptor Activation in Intact Vascular Tissue
Vascular stretch injury is associated with blunt trauma, vascular surgical procedures, and harvest of human saphenous vein for use in vascular bypass grafting. A model of subfailure overstretch in rat abdominal aorta was developed to characterize surgical vascular stretch injury. Longitudinal stretch of rat aorta was characterized ex vivo. Stretch to the haptic endpoint where the tissues would no longer lengthen, occurred at twice the resting length. The stress produced at this length was greater than physiologic mechanical forces but well below the level of mechanical disruption. Functional responses were determined in a muscle bath and this subfailure overstretch injury led to impaired smooth muscle function that was partially reversed by treatment with purinergic receptor (P2X7R) antagonists. These data suggest that vasomotor dysfunction caused by subfailure overstretch injury may be due to activation of P2X7R. These studies have implications for our understanding of mechanical stretch injury of blood vessels and offer novel therapeutic opportunities.
- Open Access
- 1 August 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (2) , 471-478
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia
- 1 August 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (2) , 471-478
Open AccessUse of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia